View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Emmanuel Matot
  • Emmanuel Matot

Soitec : Valuation and sector newsflow offer support for a future reco...

The sector newsflow is improving but the valuation is at a low (P/B = 1x, EV/EBITDA ratio identical to that of Siltronic). We remain positive on the stock (target price raised from € 54 to € 58 on a reduction in the governance discount). In the short term, the size of inventories at customers justifies a further reduction in our earnings estimates.

Emmanuel Matot
  • Emmanuel Matot

Soitec : La valorisation et le newsflow sectoriel en soutien pour un f...

Alors que le newsflow sectoriel s’améliore, la valorisation est au plus bas (P/B = 1x, VE/EBITDA identique à Siltronic…). Nous restons positifs sur la valeur (objectif relevé de 54 € à 58 € avec la réduction de la décote de gouvernance). A court terme, l’ampleur des stocks chez les clients justifie de baisser de nouveau nos prévisions de résultats.

 PRESS RELEASE

Combined General Meeting of July 22, 2025 Conditions for Obtaining th...

Combined General Meeting of July 22, 2025 Conditions for Obtaining the Preparatory Documents COMBINED GENERAL MEETINGOF JULY 22, 2025 CONDITIONS FOR OBTAINING THE PREPARATORY DOCUMENTS Bernin (Grenoble), France, on July 1, 2025 - Soitec (Euronext Paris) reminds that the Company’s shareholders are invited to attend the Annual General Meeting to be held on Tuesday July 22, 2025 at 9:30 a.m. (Paris time), in the Auditorium of the VERSO conference Center located at 52 rue de la Victoire, 75009 Paris, France. The preliminary meeting notice serving as convening notice as provided for ...

 PRESS RELEASE

ASSEMBLEE GENERALE MIXTE DU 22 JUILLET 2025 MODALITÉS DE MISE À DISPO...

ASSEMBLEE GENERALE MIXTE DU 22 JUILLET 2025 MODALITÉS DE MISE À DISPOSITION DES DOCUMENTS PRÉPARATOIRES   ASSEMBLEE GENERALE MIXTEDU 22 JUILLET 2025 MODALITÉS DE MISE À DISPOSITION DES DOCUMENTS PRÉPARATOIRES Bernin (Grenoble), France, le 1er juillet 2025 - Soitec (Euronext Paris) rappelle que les actionnaires de la Société sont invités à participer à l’Assemblée Générale Mixte qui se tiendra le mardi 22 juillet 2025 à 9 heures 30 (heure de Paris), à l’Auditorium du Centre de conférences VERSO situé 52 rue de la Victoire, 75009 Paris. L’avis de réunion, valant avis de convocati...

Transgene Sponsored Research Strong TG4050 Data Presented at ASCO

Transgene presented two-year follow-up results from their Ph1 trial of TG4050, an individualised neoantigen therapeutic cancer vaccine, at ASCO. The data demonstrated clinical proof of principle in the adjuvant treatment of head and neck cancer.

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

Transgene - Strong TG4050 Data Presented at ASCO (Sponsored Research, ...

Transgene presented two-year follow-up results from their Ph1 trial of TG4050, an individualised neoantigen therapeutic cancer vaccine, at ASCO. The data demonstrated clinical proof of principle in the adjuvant treatment of head and neck cancer. TG4050 monotherapy generated durable immune responses lasting up to two years and met all trial endpoints, including disease-free survival, immune activation and safety. Remarkably, 100% of patients treated with TG4050 remained disease-free - an exceptio...

 PRESS RELEASE

Transgene Completes Initial Patient Screening in Phase II Part of TG40...

Transgene Completes Initial Patient Screening in Phase II Part of TG4050 Trial in Operable Head and Neck Cancer Phase I part showed 100% Disease-Free Survival (DFS) after a minimum of 2-year follow-up – providing clinical proof of principle for TG4050 Randomization of all patients expected to be completed by end 2025 First immunogenicity data of Phase II part expected in H2 2026 Preliminary efficacy data expected in H2 2027 Strasbourg, France, June 19, 2025, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for th...

 PRESS RELEASE

Transgene finalise la sélection initiale de patients pour la partie Ph...

Transgene finalise la sélection initiale de patients pour la partie Phase II de l’essai avec TG4050 dans le cancer de la tête et du cou opérable 100 % de survie sans récidive après au moins deux ans de suivi des patients de la partie Phase I de l’essai – preuve de principe clinique démontrée pour TG4050 La randomisation des patients devrait être finalisée d’ici la fin de l’année 2025 Les premières données d’immunogénicité de la partie Phase II sont attendues au deuxième semestre 2026 Les données préliminaires d’efficacité sont attendues au deuxième semestre 2027 Strasbourg, France, 1...

Pierre FerraguÊ
  • Pierre FerraguÊ

The Tech Infrastructure Quarterly Bible 1Q25

We publish today our comprehensive quarterly bible: 237 pages of detailed analyses on what happened in the last 3 months, and how we interpret it, in light of our current convictions. The first section acts as a PM summary, outlining our key findings, and latest thoughts on the semi cycle, in 6 slides.

Jeremy Garnier
  • Jeremy Garnier

ODDO : ODDO BHF Nextcap Forum: Feedback from day two

Feedback of the companies present at the ODDO BHF Nextcap Forum Company Country Market cap. (m) Company Country Market cap. (m) Accsys Technologies € 124 Hoffmann Green € 62 Afyren € 72 Hornbach € 1 451 Altri € 1 058 IDI € 537 AMG € 550 Implenia CHF 973 AmRest PLN 3 544 Jacquet Metals € 494 Arcure € 29 Kloeckner & Co € 653 Arverne 194 Knaustabbert € 144 Austriacard Holdings € 188 Lna Santé € 270 Bastide € 218 Medincell € 398 Befesa € 1 116 Nacon € 63 CAF € 1 649 N...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch